Combination of IAP inhibitors and FLT3 inhibitors

Details for Australian Patent Application No. 2007325280 (hide)

Owner Novartis AG Dana-Farber Cancer Institute, Inc.

Inventors Zawel, Leigh; Griffin, James Douglas

Agent Davies Collison Cave

Pub. Number AU-B-2007325280

PCT Pub. Number WO2008/067280

Priority 60/867,448 28.11.06 US; 60/891,088 22.02.07 US

Filing date 27 November 2007

Wipo publication date 5 June 2008

Acceptance publication date 10 March 2011

International Classifications

A61K 31/427 (2006.01) - not condensed and containing further heterocyclic rings

A61K 31/437 (2006.01)

A61K 31/553 (2006.01) - having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine

A61K 31/704 (2006.01)

A61K 31/7068 (2006.01)

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

28 May 2009 PCT application entered the National Phase

  PCT publication WO2008/067280 Priority application(s): WO2008/067280

10 March 2011 Application Accepted

  Published as AU-B-2007325280

7 July 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007325283-Ovr110 antibody compositions and methods of use

2007325259-Method of diagnosing and treating glioma